CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-18). The draft was written by AI, the existence of all 4 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 472 · Search date 2026-07-18 · Methodology v0.6

Diamine oxidase,
does it really help with Relief of headache, urticaria, and gastrointestinal symptoms attributed to food-related histamine intolerance?

30-Second Summary
C
Evidence Grade C · 40 · Safety caution
A controlled human trial found a positive total-symptom signal, but substantial limitations and conflicting evidence place the claim at the bottom of C, without confirmatory treatment evidence for everyday food-related histamine intolerance
What the
research shows
Evidence has not established that DAO supplements reliably relieve headache, urticaria, and gastrointestinal symptoms attributed to food-related histamine intolerance. However, in a randomized double-blind crossover challenge involving 39 participants, the total symptom score with DAO was significantly lower than with placebo (P=0.014), providing controlled human evidence. The positive result was a tertiary endpoint, individual symptoms were not reproducible, and evidence for treating everyday food-related histamine intolerance is limited to a manufacturer-linked open-label study of 28 participants. Poor diagnostic reproducibility further supports a grade of C for limited and conflicting evidence.
What the
ads claim
Marketing groups low serum DAO, headache, urticaria, and abdominal symptoms into a single condition of histamine excess and presents a pre-meal capsule as correction of the cause. Diagnostic criteria, food histamine content, and actual product enzyme activity remain uncertain.
*

Useful facts when choosing a product

  • Imported porcine-kidney or plant-derived DAO supplements are sold online in Korea, with product-specific HDU labeling, source material, and enteric coating.
  • The open-label study used one capsule containing 4.2 mg of porcine kidney protein with 0.3 mg of DAO before meals, up to three times daily, but actual activity and equivalence to the study product are not assured.
  • Porcine products raise vegetarian, religious, and pork-allergy issues, and evidence for safety in pregnancy, lactation, and long-term use is limited.
  • Urticaria, breathing difficulty, severe headache, or abdominal pain requires evaluation for allergy, mast-cell disorders, migraine, and gastrointestinal disease. DAO does not replace emergency treatment.
Gap Measurement · Verdict 472 · C 40
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Komericki 2011 enrolled 39 people who had reacted to an open challenge and crossed them through combinations of histamine-containing or histamine-free tea and DAO or placebo. Individual symptoms appeared unpredictably and were not reproducible, although the total symptom score was lower with DAO (P=0.014). Schnedl 2019 gave DAO before meals for four weeks to 28 patients and reported lower scores on a 22-symptom questionnaire during supplementation and higher scores after withdrawal, but there was no control group. Bent 2023 excluded histamine intolerance in most suspected patients by a placebo-controlled challenge. A 400-participant diet-by-DAO double-blind trial was published as a protocol in 2024, and no results publication was identified.

02

Why this is classified as C (40)

A randomized double-blind crossover challenge in 39 participants found a significantly lower total symptom score with DAO than with placebo (P=0.014), so controlled human evidence rules out D. However, this was a tertiary endpoint, individual symptoms were not reproducible, and evidence in everyday food-related histamine intolerance is limited to a manufacturer-linked open-label study of 28 participants. The absence of a confirmatory long-term RCT and poor diagnostic reproducibility support limited and conflicting evidence at the bottom of C with 40 points.

Counterpoint. A short-term signal may remain in selected people with a clear meal-related pattern, but current evidence cannot establish a consistent treatment effect across the composite symptoms or validate the diagnosis.

Rejudgment record. Reassessment (cross-check reflected) — Recognized the significant reduction in total symptom score (P=0.014) in a 39-participant randomized double-blind crossover trial as controlled human evidence, while also accounting for the tertiary endpoint, nonreproducible individual symptoms, the manufacturer-linked open-label study of 28 participants, poor diagnostic reproducibility, and the absence of a confirmatory long-term RCT

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Reduction of total symptom score after an acute histamine challengeCThe total score was positive in the 39-participant crossover trial (P=0.014), but it was a tertiary endpoint and individual symptoms showed no reproducible effect.
Relief of headache, urticaria, and gastrointestinal symptoms in everyday food-related histamine intoleranceDOnly small uncontrolled evidence from a manufacturer-linked open-label study of 28 participants is available, with no confirmatory long-term RCT.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Komericki P et al. 2011Multicenter randomized double-blind placebo-controlled crossover challenge39Unknown; commercial DAO capsules usedIndividual main and secondary symptoms and total symptom scoreIndividual symptoms were not reproducible, but the tertiary total symptom score was lower with DAO than placebo (P=0.014).Key
Schnedl WJ et al. 2019Open-label intervention and withdrawal pilot28One author was affiliated with a DAO manufacturer; product suppliedSum and severity of 22 symptomsSymptom scores fell during four weeks of supplementation and rose after withdrawal, but there was no control group.Supportive
Bent RK et al. 2023Single-blind placebo-controlled diagnostic histamine challenge59Academic researchResponses to histamine and placebo and diagnostic classificationSymptoms occurred with placebo in 62.7%, and histamine intolerance was excluded in 84.7%.Diagnostic context
Duelo A et al. 2024Protocol for a 400-participant double-blind randomized trial400Spanish public and academic research supportSymptom effects of a low-histamine diet and porcine or plant DAOOnly the confirmatory trial design has been published; no efficacy results publication was identified.Ongoing
§

Receipt — 4 References

All 4 cited sources were verified for existence at the original page (as of 2026-07-18).

Komericki P, Klein G, Reider N, et al. Histamine intolerance: lack of reproducibility of single symptoms by oral provocation with histamine: a randomised, double-blind, placebo-controlled cross-over study. Wien Klin Wochenschr. 2011;123(1-2):15-20. PMID: 21165702. DOI: 10.1007/s00508-010-1506-y.
checked
Schnedl WJ, Schenk M, Lackner S, Enko D, Mangge H, Forster F. Diamine oxidase supplementation improves symptoms in patients with histamine intolerance. Food Sci Biotechnol. 2019;28(6):1779-1784. PMID: 31807350. PMCID: PMC6859183. DOI: 10.1007/s10068-019-00627-3.
checked
Bent RK, Kugler C, Faihs V, Darsow U, Biedermann T, Brockow K. Placebo-Controlled Histamine Challenge Disproves Suspicion of Histamine Intolerance. J Allergy Clin Immunol Pract. 2023;11(12):3724-3731.e11. PMID: 37648152. DOI: 10.1016/j.jaip.2023.08.030.
checked
Duelo A, Sanchez-Perez S, Ruiz-Leon AM, et al. Study Protocol for a Prospective, Unicentric, Double-Blind, Randomized, and Placebo-Controlled Trial on the Efficacy of a Low-Histamine Diet and DAO Enzyme Supplementation in Patients with Histamine Intolerance. Nutrients. 2025;17(1):29. PMID: 39796463. PMCID: PMC11723128. DOI: 10.3390/nu17010029.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-18 · Corrections: none

Cite this verdict

Diamine oxidase x relief of symptoms attributed to food-related histamine intolerance Evidence Grade C card
[Chamgap] Diamine oxidase x relief of symptoms attributed to food-related histamine intolerance — Evidence Grade C·40. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/general/dao-histamine-intolerance-symptoms/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.